September 4 @ 9:00 AM – 1:30 PM
Join the Johnson & Johnson Innovation – JLABS @ Washington, DC on Wednesday, Sept. 4 as the team welcomes experts from in key areas of consideration for any innovator in the midst of growing an early-stage life science company or considering it. Wilson Sonsini, Silicon Valley Bank, and Browne Consulting will provide short presentations on their area of expertise to be followed by open office hours.
Browne Consulting Presentation: Due Diligence and Corporate Hygiene
With a continuously challenging funding landscape, it’s more important than ever to put your company in an ‘investible’ position before funding opportunities emerge. Leveraging their visibility into over 130 early-stage life science companies, Browne will cover best practices for areas including but not limited to: corporate records management, budgeting, tax compliance, equity issuances, and compliance related to payroll and benefits.
WSGR Presentation: Mastering IP Diligence for VC Investments and BioPharma Partnering
To make informed investment decisions and assess the risks and opportunities effectively, life science venture capitalists and biopharma must conduct thorough IP diligence when evaluating potential opportunities in this space. We’ll take you step by step through the IP diligence process and will cover the six primary areas that we investigate when conducting an IP diligence on a target company for an investment. This will include discussion around patent strategy, chain of title issues, patentability and invalidity, scope of coverage, freedom-to-operate, and minimizing a company’s exposure to patent litigation. We’ll cover some black letter law but will focus mainly on hypotheticals that are inspired by some real-life examples we’ve encountered when conducting IP diligence. We hope our discussion will provide some informative best practices to help you prepare and get ahead of avoidable problems that can have the potential to hold up a financing or a deal.
SVB Panel: SVB’s H1 2024 Healthcare Investments and Exits Report: Focus on Therapeutics
In this presentation & panel discussion, we deep dive into the published 2024 H1 annual report, highlighting data pertinent to therapeutics investments. A discussion focusing on 2024 H1 and what is expected for H2 will follow, touching on several topics including therapeutic area focus, how early are investors willing to deploy capital, and what a CEO should do to increase runway if investment deployment remains challenging.